FIG 5.

Assay specificity. (A) SARS-CoV-2 spike trimers versus non-SARS-CoV-2 anti-RSV 1g7-TM-YTE antibody. RSV antibody used in the association phase with either the wild-type trimer or D614G. (B) SARS-CoV-2 spike trimers versus ICAM-Fc. ICAM-Fc used in the association phase with either the wild-type trimer or D614G. ICAM-Fc started at 1 μM to match concentrations of ACE2-Fc. (C) Nonspecific binding with mock trimer. Mock transfection was used as trimer in the load phase of the assay. Association and dissociation are shown for the four analytes that did not show any evidence of binding. (D) Nonspecific binding with RSV A2 trimer. RSV trimer was used in the load phase of the assay. Association and dissociation are shown for the four analytes that did not show any evidence of binding. (E) CV7 versus mock trimer and RSV A2 trimer. Left, nonspecific binding of CV7 with mock trimer with the corresponding concentrations listed. Right, nonspecific binding of CV7 with RSV trimer with the corresponding concentrations listed. Mock trimer is buffer-exchanged transfection supernatant. Panels show the association (0 to 180 s) and dissociation (180 to 780 s) phase for each test. ICAM, intercellular adhesion molecule; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.